BLTE logo

BLTEBelite Bio Inc

$143.35
$1.11
(0.77%)
Today
Closed $143.35
$0.00
(0.00%)
After Hours
Updated: 05:55 PM EDT
Reported EarningsMay 20
Mkt Cap$5.75B
Vol333,834.00
News
all
press releases
Full Transcript: Belite Bio Q1 2026 Earnings Call
read more...
Benzinga
News Placeholder
More News
News Placeholder
Belite Bio Enters Oversold Territory (BLTE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
News Placeholder
Belite Bio (BLTE) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
Nathan Mata Sells 1,000 Shares of Belite Bio (NASDAQ:BLTE) Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of Belite Bio stock in a transaction on Tuesday, May 5th. The stock was sold at an average price...
MarketBeat
News Placeholder
Belite Bio (BLTE) Projected to Post Quarterly Earnings on Tuesday
Belite Bio (NASDAQ:BLTE) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-belite-bio-inc-stock...
MarketBeat
News Placeholder
Insider Selling: Belite Bio (NASDAQ:BLTE) Insider Sells 1,000 Shares of Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the firm's stock in a transaction on Wednesday, April 29th. The shares were sold at an average...
MarketBeat
News Placeholder
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the firm...
MarketBeat
News Placeholder
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the company's stock in a transaction dated Wednesday, April 29th. The shares were sold at an...
MarketBeat
News Placeholder
Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average...
MarketBeat
News Placeholder
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference
Belite Bio (NASDAQ:BLTE) highlighted progress for its lead drug candidate tinlarebant during the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference, outlining late-stage clinical...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.